Evidence map›Paper›PMID 35187624›Full record

ArticleAnnals of surgical oncology2022

Prognostic Effect of Aberrant Right Hepatic Artery with Pancreaticoduodenectomy: Focus on Hepatic Recurrence.

Christopher W Mangieri, Cristian D Valenzuela, Richard A Erali, Perry Shen, Russell Howerton, Clancy J Clark

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Christopher W MangieriDepartment of Surgery, Surgical Oncology Section, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA. cmangier@wakehealth.edu.ORCID http://orcid.org/0000-0003-0633-9454
Cristian D ValenzuelaDepartment of Surgery, Surgical Oncology Section, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
Richard A EraliDepartment of Surgery, Surgical Oncology Section, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
Perry ShenDepartment of Surgery, Surgical Oncology Section, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
Russell HowertonDepartment of Surgery, Surgical Oncology Section, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
Clancy J ClarkDepartment of Surgery, Surgical Oncology Section, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
Atrium Health Wake Forest Baptist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetastatic progression occurs along the locoregional vasculature, and a common anatomic variant is an aberrant right hepatic artery (aRHA). This study evaluated the effect of an aRHA following pancreaticoduodenectomy, with a focus on hepatic metastases.

methodsThis was a single-institution retrospective review of non-metastatic pancreatic cancer cases between 2012 and 2020. aRHA cases were compared with patients with conventional anatomy. The primary outcome was hepatic recurrence rates, while secondary analysis survival outcomes were measured by overall survival (OS) and disease-free survival (DFS). Subgroup analysis was stratified by tumor resectability and utilization of systemic therapy.

resultsOverall, 207 cases were reviewed, with 17.4% having aRHA anatomy. On multivariate analysis, aRHA increased hepatic recurrence for all-comers (odds ratio [OR] 4.76, 95% confidence interval [CI] 2.18-10.38; p < 0.001). aRHA was significant for resectable tumors (OR 2.58, 95% CI 1.89-6.66; p = 0.045) and borderline resectable tumors (OR 28.88, 95% CI 5.52-151.18; p < 0.0001) in regard to hepatic recurrence on univariate analysis. Increased hepatic recurrence correlated with decreased 3-year OS and DFS rates of 30.6% versus 50.3% (OR 0.44, 95% CI 0.20-0.94; p = 0.032) and 13.6% versus 36.9% (OR 0.27, 95% CI 0.08-0.97; p = 0.035). Systemic therapy limited the effects of aRHA.

conclusionaRHA was associated with inferior survival outcomes due to the significantly increased risk of hepatic metastatic disease with aberrant anatomy. This study provides important prognostic information for a commonly encountered anatomic variant.

Indexed as

Liver NeoplasmsPancreatic NeoplasmsHepatic ArteryHumansPancreatectomyPancreaticoduodenectomyPrognosis

Identifiers

PMID35187624
OpenAlexW4213348967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.